London and New York-listed Sensodyne maker Haleon agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14).
Total consideration for the stake acquisition is 4.47 billion yuan, according to a Sept. 27 press release.
The deal will increase Haleon's equity interest in Tianjin TSKF Pharmaceutical to 88% from 55%.
Also, Haleon secured an option to acquire Tianjin Pharmaceutical Da Ren Tang Group's remaining 12% shareholding in Tianjin TSKF Pharmaceutical.
Tianjin TSKF Pharmaceutical manufactures and distributes brands such as Fenbid, Voltaren and Bactroban.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。